SUMMIT THERAPEUTICS INC (SMMT) Stock News
NASDAQ:SMMT - Nasdaq - US86627T1088 - Common Stock - Currency: USD
SMMT Latest News, Press Relases and Analysis
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Is Summit Therapeutics a Millionaire Maker?
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There'
On CNBC's "Mad Money Lightning Round," Jim Cramer said Summit Therapeutics is "obviously just a very big spec."
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. BTIG analyst Justin Zelin thinks Viking Therapeutics stock can reach $125 per share for a gain of about 166% over the next 12 months. If an experimental weight loss treatment it's developing continues to succeed in clinical trials, the stock could more than double again.
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
While chipmaker Nvidia is an obvious example of a top growth stock to own given its more than 2,500% return over the past five years, there are many other stocks that have produced incredible gains in a short stretch. Three stocks that have done phenomenally well this year and have outperformed Nvidia are AppLovin (NASDAQ: APP), MicroStrategy (NASDAQ: MSTR), and Summit Therapeutics (NASDAQ: SMMT). If you invested $5,000 into each one of these stocks at the beginning of the year, the total of those investments would be worth more than $100,000 right now.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics to Present at Upcoming Investor Conferences
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China.
Mentions: MRK
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts